Investor Presentation

Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417 www.biocon.com BIO/SECL/TG/2026-27/51 August 06, 2026 To, To, The Secretary The Secretary BSE Limited National Stock Exchange of India Limited Department of Corporate Services, Corporate Communication Department, Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla Complex, Dalal Street, Mumbai – 400 001 Mumbai – 400 051 Scrip Code - 532523 Scrip Symbol - BIOCON Dear Sir/Madam, Subject: Presentation – Q1 FY27 Earnings Call Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the presentation w.r.t. Q1 FY27 Earnings Call to be conducted on August 06, 2026. The above information will also be available on the website of the Company at www.biocon.com. Kindly take the above information on record. Thanking You, Yours faithfully, For Biocon Limited Rajesh U. Shanoy Company Secretary and Compliance officer ICSI Membership Number: A16328 Enclosed: as above Biocon Limited Q1 FY27 Earnings Call 06 – Aug – 2026 Safe Harbor Statement Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither the company, nor its directors and any of the affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition. Chairperson’s Opening Remarks Positioned for the Next Phase of Growth ▪ Integrated platform, global scale and resilient supply networks position Biocon for sustained growth ▪ North America: largest strategic market, policy tailwinds and launch execution ⁻ Affordability and access remain central to policy dialogue ⁻ Recent US commercialization: Yesafili (bAflibercept), Bosaya & Aukelso (bDenosumab), gLiraglutide ⁻ Regional supply network strengthened through local capabilities and strategic partnerships ▪ Europe: integrated portfolio in a well-established biosimilars and generics market ⁻ Combined portfolio of 11 biosimilars and eight generic medicines ⁻ Tailored retail and tender strategies ⁻ Evfraxy® (bDenosumab) and Abevmy® (bBevacizumab) launches across select markets ▪ Emerging Markets: access led growth through portfolio breadth and partnerships ⁻ Broader portfolio with expanded commercial capabilities ⁻ Local partnerships, CMOs and technology-transfer initiatives ⁻ Yesafili launch in Malaysia; continued bevacizumab leadership in Brazil Financial Highlights – Q1 FY27 Financial Highlights – Q1 FY27 In ₹ Cr Q1 FY27 Q1 FY26 Q4 FY26 YoY% QoQ% Biopharmaceuticals - Biosimilars 2,855 2,458 2,756 16 4 - Generics 760 630* 776* 21 (2) Services 736 875 1,037 (16) (29) Revenue from Operations 4,336 3,942 4,517 10 (4) Total Revenue 4,391 4,022 4,569 9 (-4) R&D (Net) 240 205 277 17 (13) % of Revenue (Ex. Syngene) 7 7 8 EBITDA 902 846 1,073 7 (16) % Margin 21 21 23 Profit Before Tax 141 114 328 24 (57) (Before exceptional items) % Margin 3 3 7 Net Profit 145 42 179 245 (19) (Before exceptional items) Exceptional item, net of tax & NCI (4) (11) (53) Net Profit (Reported) 141 31 126 355 12 * Excluding cross charge of common utilities that was earlier included within Generics but is now appropriately included under “Unallocable expenditure/(income)” Biosimilars Biosimilars: Q1 FY27 Business Performance Update ▪ Financial Performance In ₹ Cr Q1 FY27 Q1 FY26 Q4 FY26 YoY% QoQ% ⁻ Growth led primarily by North America market Segment ⁻ EBITDA up 10% YoY, 25% EBITDA margin 2,855 2,458 2,756 16 4 Revenue ⁻ R&D spend at 7% of revenue R & D 192 134 188 44 2 ▪ Growth momentum expected to build progressively % of through FY27, H2 to be meaningfully better 7% 5% 7% Revenue ▪ Recent launches and market access progress provide EBITDA 728 662 720 10 1 visibility on a stronger second half % of 25% 27% 26% Revenue ▪ EMA approval for second insulin drug product line in Malaysia doubles capacity and supports future growth Generics Generics: Q1 FY27 Business Performance Update ▪ Financial Performance In ₹ Cr Q1 FY27 Q1 FY26* Q4 FY26* YoY% QoQ% ⁻ Revenues up 21% YoY Segment ⁻ EBITDA margin up by over 250bps QoQ 760 630 776 21 (2) Revenue ⁻ R&D spend at 6% of revenue R & D 47 70 89 (33) (47) ▪ Generic liraglutide was a key driver across multiple % of markets, including the USA 6% 11% 12% Revenue ▪ Margin improvement driven by operating leverage EBITDA 56 (35) 39 nm 44 and cost efficiency initiatives % of 7% (6)% 5% Revenue ▪ Peptides, fermentation and manufacturing investments provide a strong platform for utilization- led margin expansion * Excluding cross charge of common utilities that was earlier included within Generics but is now appropriately included under “Unallocable expenditure/(income)” Services Services: Q1 FY27 Business Performance Update ▪ Financial Performance ⁻ Performance impacted by lower offtake from a key biologics In ₹ Cr Q1 FY27 Q1 FY26 Q4 FY26 YoY% QoQ% client and forex hedge losses Segment ⁻ Partly offset by cost optimization initiatives 736 875 1,037 (16) (29) Revenue ▪ Strengthening Capabilities EBITDA 116 224 326 (48) (64) ⁻ Strategic collaboration with BRIC-THSTI* enhances translational research and clinical development capabilities % of ⁻ Continued investment in Syn.AI@, digital technologies and 15% 25% 31% Revenue emerging modalities ▪ Outlook ⁻ FY27 to be a transition year, with performance improving in 2H ⁻ New management team focused on sharpening commercial execution, strengthening delivery and building a more agile, cost-competitive organisation ⁻ Positioned for a return to sustainable growth from FY28 * Biotechnology Research & Innovation Council - Translational Health Science and Technology Institute; @Syngene’s AI-enabled scientific platform for accelerating drug discovery services Concluding Remarks Concluding Remarks: Q1 FY27 ▪ Growth Momentum Building ⁻ Recent launches and expanded manufacturing capacity support the next phase of growth ⁻ Performance expected to strengthen through FY27, led by Biosimilars ▪ Translating Scale into Returns ⁻ Focused on improving margins, free cash flow generation and RoCE ⁻ Generics profitability showing early benefits of operating leverage and fiscal prudence ▪ Positioned for Sustainable Value Creation ⁻ Integrated portfolio and global capabilities position us well for future opportunities ⁻ Committed to translating growth into stronger earnings and shareholder value Thank you